Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TI-0010 COVID-19 Vaccine in Healthy Adults
NCT06205524Phase 1Recruiting
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, Long Non-coding RNA (lncRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TI-0010 in coronavirus disease 2019 (COVID-19) (4 cohorts). Primary endpoints: Solicited Adverse Events and Incidence of Abnormal Changes in Laboratory Indicators. Started Jul 2023; status: recruiting.
02
Drugs
TI-0010
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06205524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205524.